2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2731

Th1 and Th17 Cytokines Drive Takayasu Arteritis Inflammation
Abstract Number: 1622

Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus
Abstract Number: 1602

Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis
Abstract Number: 397

Th9 Lymphocytes in Rheumatoid Arthritis
Abstract Number: 958

The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Long-term Immunosuppression of Lupus Nephritis
Abstract Number: 2383

The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry
Abstract Number: 1442

The 2013 ACC/AHA Cardiovascular Risk Prediction Model and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 336

The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit
Abstract Number: 1692

The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
Abstract Number: 991

The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis
Abstract Number: 2954

The Amino Acid Positions 11, 13 and 26 of HLA-DR Beta Chain 1 Explain the Majority of the Association Between Systemic Lupus Erythematosus and the Major Histocompatibility Complex Locus
Abstract Number: 613

The Amount of Free Heavy Chain and β2-Microglobulin in the Cytoplasm of B*2705 Ankylosing Spondylitis Patients Compared to B*2705 and B*2709 Healthy Subjects Does Not Support the UPR Theory. Influence of ERAP1 Polymorphisms
Abstract Number: 2577

The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 759

The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By Urokinase
Abstract Number: 439

The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].